Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments

As a catalytic subunit of the positive transcription elongation factor b (P-TEFb), cyclin-dependent kinase 9 (CDK9) has been demonstrated to contribute to carcinogenesis. This review focuses on the development of selective CDK9 inhibitors and proteolysis-targeting chimera (PROTAC) degraders. Twenty...

Full description

Bibliographic Details
Main Authors: Lanshu Xiao, Yi Liu, Hui Chen, Lisong Shen
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Cancer Biology & Therapy
Subjects:
cdk9
small molecular inhibitors
protac degraders
tumor
targeted therapy
development
Online Access:http://dx.doi.org/10.1080/15384047.2023.2219470

Similar Items

Similar Items